ArticleFrontiers in cellular and infection microbiology2023
Clinical features and "early" corticosteroid treatment outcome of pediatric
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Systemic Corticosteroids in Pediatric Community-Acquired Pneumonia: Evidence, Clinical Outcomes, and Phenotype-Based Therapeutic Considerations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficacy of High-Dose Versus Conventional-Dose Methylprednisolone in Reducing the Risk of Chronic Lung Disease in Chinese Children With Severe Mycoplasma pneumoniae Pneumonia: A Retrospective Study.Pediatric pulmonology · 2026Article
- A2063G macrolide-resistant Mycoplasma pneumoniae: epidemic dominance without more frequent pulmonary consolidation or worse short-term in-hospital outcomes in hospitalized children.BMC pediatrics · 2026Article
- Comprehensive analysis of factors to consider when using glucocorticoids for sCAP: A review.Medicine · 2026Review
- Mycoplasma pneumoniae infection impairs asthma control in pediatric patients and exacerbates allergic airway inflammation.Respiratory research · 2026Article
- Correlation analysis of serum CHI3L1, HMGB1, and CD62E detection with the prognosis of Mycoplasma pneumoniae in children.Journal of medical biochemistry · 2026Article
- Pathogenesis and Risk Factors of Post-Infectious Bronchiolitis Obliterans in Children: A Focus on Adenovirus and Mycoplasma Infections.Pathogens (Basel, Switzerland) · 2026Review
- Diagnostic value of cytokine detection in children with Mycoplasma pneumoniae pneumonia complicated by bacterial or viral co-infections.BMC pediatrics · 2026Article
- Clinical efficacy comparison of Doxycycline versus Azithromycin combined with Methylprednisolone in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- Comparison of severe and general Mycoplasma pneumoniae pneumonia in children: a targeted next-generation sequencing based study.BMC infectious diseases · 2026Article
- A novelJournal of clinical microbiology · 2026Article
- Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children.Frontiers in pediatrics · 2026Article
- Clinical characteristics of Mycoplasma pneumoniae pneumonia in children with atopic constitution and risk factors for disease severity: a retrospective comparative study.Frontiers in pediatrics · 2026Article
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Impact of COVID-19 on the epidemiological features of mycoplasma pneumoniae infection in children with community-acquired pneumonia in Ganzhou, China.Frontiers in immunology · 2026Article
- Comparison of Different Corticosteroid Regimens for RefractoryInfection and drug resistance · 2026Article
- Prediction models for refractoryFrontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many children with Methods: Patients who had pulmonary infiltrations on chest imaging within 5 days of the disease course and were suspected of having MP infection on admission were enrolled. Among them, patients whose disease course was within 10 days on admission were ultimately enrolled. We analyzed their data including the clinical features, the starting time and dose of corticosteroid therapy, and the treatment outcome. According to chest imaging, we divided patients into two groups (Group A: bronchiolitis-associated lesions or ground-glass opacities; Group B: pulmonary segmental/lobar consolidation). Results: A total of 210 patients with confirmed MPP were ultimately enrolled. There were 59 patients in Group A and 151 patients in Group B. Patients in Group A were more prone to have allergy histories, hypoxemia, wheezing sound, and wet rales on auscultation than those in Group B. Corticosteroid treatment was initiated between 5 and 10 days of disease onset in all patients and 6-7 days in most patients. Methylprednisolone was prescribed in all patients within 10 days of disease onset, and the highest prescribed dose was at least 2 mg/kg/day. In Group A, methylprednisolone >2 mg/kg/day was prescribed in 22 patients, and among them, 8 patients with diffuse bronchiolitis-associated lesions received high-dose methylprednisolone therapy. After 3 months, lung CT revealed slightly segmental ground-glass opacity in three patients. In Group B, methylprednisolone >2 mg/kg/day was prescribed in 76 patients, and among them, 20 patients with pulmonary lobar consolidation received high-dose methylprednisolone therapy. After 3 months, chest imaging revealed incomplete absorption of pulmonary lesions in seven patients. Among them, five patients with consolidation in more than one pulmonary lobe ultimately had slight BO. Conclusion: In hospitalized patients with MPP, particularly severe MPP, the ideal starting time of corticosteroid treatment might be 5-10 days, preferably 6-7 days, after disease onset. The initial dosage of corticosteroid therapy should be decided according to the severity of the disease. MPP patients with diffuse bronchiolitis-associated lesions/whole lobar consolidation on imaging might require high-dose corticosteroid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.